Cargando…

Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial

OBJECTIVE: The phase III POLO trial demonstrated that olaparib as maintenance therapy for metastatic pancreatic cancer patients with a germline BRCA mutation had greater efficacy than placebo, but maintenance olaparib places an economic burden on patients. This study evaluated the cost-effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhan, Mei, Zheng, Hanrui, Yang, Yu, He, Zhiyao, Xu, Ting, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751318/
https://www.ncbi.nlm.nih.gov/pubmed/33364840
http://dx.doi.org/10.2147/CMAR.S283169